VivoSeq
Oncology

Solid Tumours

6

Pipeline Programs↗

26

Active Trials↗

25

Companies Involved↗

Solid Tumours is an early-stage landscape with 6 programs across 25 companies. The most active players are AstraZeneca, Genmab, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

27/100

Mech. Concentration

100/100

Completion Rate

76/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

3 programs

Phase 1Genmab logo

Genmab

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

3 programs

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

PreclinicalH

Heidelberg Pharma AG

0 programs

PreclinicalRoche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

4 of 6 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody233%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 75% of 8 pipeline programs.

Analysis

Trial Status

75

clinical trials

Completed35 · 47%
Recruiting16 · 21%
Terminated9 · 12%
Active, not recruiting8 · 11%
Unknown status3 · 4%
Not yet recruiting2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

75 trials

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.
Recruiting·RRace Oncology Ltd·Phase 1·NCT06815575·53 enrolled
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Recruiting·AAvacta Life Sciences Ltd·Phase 1·NCT04969835·158 enrolled
A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours
Recruiting·PPharmaMatrix Holdings Ltd·Phase 1·NCT04823897·70 enrolled
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients with Solid Tumours
Recruiting·GGrit Biotechnology·N/A·NCT06453057·18 enrolled
Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours
Recruiting·GGrit Biotechnology·N/A·NCT06397963·18 enrolled
CD8 PET Imaging in Metastatic Solid Tumours
Recruiting·UUniversity Medical Center Groningen·Phase 2·NCT06534190·30 enrolled
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
Recruiting·LLeucid Bio·Phase 1/2·NCT06193902·17 enrolled
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Recruiting·AAuricula Biosciences Inc.·Phase 1/2·NCT07148128·110 enrolled
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours
Recruiting·—·Phase 1·NCT05759923·40 enrolled
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Recruiting·AAccession Therapeutics Limited·Phase 1/2·NCT06977737·72 enrolled
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Recruiting·FFilamon LTD·Phase 1/2·NCT06926075·80 enrolled
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Recruiting·PPathios Therapeutics Pty Ltd·Phase 1/2·NCT06634849·30 enrolled
A Phase I, Multicentre, Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab in Adult Participants With Solid Tumours
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT07391670·40 enrolled
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT06581432·430 enrolled
A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy in Adult Participants With Advanced Solid Tumors
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Preclinical·NCT07160725·315 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)